tcsc0018139 RGH-5526

GYKI-11679 is a new antihypertensive agent.

In Vivo: GYKI-11679 is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of GYKI-11679, and this effect lasts for 4 to 6 h. It is demonstrated that GYKI-11679 exerts a greater NA lowering effect in the hypothalamus than in the periphery. GYKI-11679 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment^[1].